"Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS," published by Amylyx Pharmaceuticals
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS